Intellia Therapeutics Inc (NTLA)
EBITDA Growth
-5.84%
Quarterly · Period ending:
NTLA EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-5.84%period ending
Latest reported-5.84%period ending
NTLA Quarterly EBITDA YoY % (-28.07% → -5.84%)
Year-over-year change
High-resolution chart · PNG
NTLA ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -5.8422% | |
| 15.9187% | |
| 24.4776% | |
| 27.5844% | |
| 31.5807% | |
| -6.5829% | |
| 2.593% | |
| -10.981% | |
| -18.8172% | |
| -3.807% | |
| -16.4479% | |
| -7.7777% | |
| -22.9358% | |
| 30.3491% | |
| -40.348% | |
| -59.2931% | |
| -47.1461% | |
| -223.6785% | |
| -94.5168% | |
| -163.6151% | |
| -113.4613% | |
| -42.2985% | |
| -44.7318% | |
| -10.6703% | |
| -20.4655% | |
| -39.9751% | |
| -44.4131% | |
| -4.3492% | |
| -15.9844% | |
| -5.0938% | |
| 18.269% | |
| -52.118% | |
| -47.1449% | |
| -74.3001% | |
| -129.2599% | |
| -102.9736% | |
| -128.4819% | |
| -88.8428% | |
| -94.3833% | |
| -131.8877% | |
| -99.6721% | |
| -459.9828% | |
| -28.0679% |